Papers/PMID:42514320
Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis.
Nutrients2026The record
7 findings · 1 compound · 7 endpoints · 6 null
What it reported
How to read these marksWhat moved
1 finding
NMN zwitterion — decreases diastolic blood pressure (setting unspecified)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“NMN supplementation was associated with a small but significant reduction in diastolic blood pressure (MD = −2.43 mmHg, 95% CI −4.21 to −0.66, p = 0.007, I2 = 0%).”
Quoted verbatim from Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Dose
- 250-2000 mg/day oral across included trials
- Population
- Adults in randomized controlled trials of oral NMN or NMN-related preparations (including MIB-626) against placebo or no-NMN controls; random-effects pooled analysis of 11 comparisons
Effect -2.43 mean difference, 95% CI -4.21 to -0.66
Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis.2026PMID:42514320Permalink
What did not
6 findings
NMN zwitterion — no detected effect on alanine aminotransferase
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“NMN supplementation did not significantly alter ALT levels: MD = −1.03 U/L, 95% CI −2.51 to 0.44, p = 0.169, I2 = 0%.”
Quoted verbatim from Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Dose
- 250-2000 mg/day oral across included trials
- Population
- Adults in randomized controlled trials of oral NMN or NMN-related preparations (including MIB-626) against placebo or no-NMN controls; random-effects pooled analysis of 10 comparisons
Effect -1.03 mean difference, 95% CI -2.51 to 0.44
Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis.2026PMID:42514320Permalink
NMN zwitterion — no detected effect on aspartate aminotransferase
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“NMN supplementation did not significantly alter AST levels: MD = −0.24 U/L, 95% CI −1.43 to 0.94, p = 0.686, I2 = 0%.”
Quoted verbatim from Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Dose
- 250-2000 mg/day oral across included trials
- Population
- Adults in randomized controlled trials of oral NMN or NMN-related preparations (including MIB-626) against placebo or no-NMN controls; random-effects pooled analysis of 10 comparisons
Effect -0.24 mean difference, 95% CI -1.43 to 0.94
Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis.2026PMID:42514320Permalink
NMN zwitterion — no detected effect on triglycerides
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Regarding lipid indicators, NMN supplementation had no significant effect on HDL-C, LDL-C, total cholesterol, or triglycerides.”
Quoted verbatim from Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Dose
- 250-2000 mg/day oral across included trials
- Population
- Adults in randomized controlled trials of oral NMN or NMN-related preparations (including MIB-626) against placebo or no-NMN controls; random-effects pooled analysis
Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis.2026PMID:42514320Permalink
NMN zwitterion — no detected effect on HDL cholesterol
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Regarding lipid indicators, NMN supplementation had no significant effect on HDL-C, LDL-C, total cholesterol, or triglycerides.”
Quoted verbatim from Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Dose
- 250-2000 mg/day oral across included trials
- Population
- Adults in randomized controlled trials of oral NMN or NMN-related preparations (including MIB-626) against placebo or no-NMN controls; random-effects pooled analysis
Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis.2026PMID:42514320Permalink
NMN zwitterion — no detected effect on LDL cholesterol
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Regarding lipid indicators, NMN supplementation had no significant effect on HDL-C, LDL-C, total cholesterol, or triglycerides.”
Quoted verbatim from Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Dose
- 250-2000 mg/day oral across included trials
- Population
- Adults in randomized controlled trials of oral NMN or NMN-related preparations (including MIB-626) against placebo or no-NMN controls; random-effects pooled analysis
Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis.2026PMID:42514320Permalink
NMN zwitterion — no detected effect on total cholesterol (TC)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Regarding lipid indicators, NMN supplementation had no significant effect on HDL-C, LDL-C, total cholesterol, or triglycerides.”
Quoted verbatim from Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Dose
- 250-2000 mg/day oral across included trials
- Population
- Adults in randomized controlled trials of oral NMN or NMN-related preparations (including MIB-626) against placebo or no-NMN controls; random-effects pooled analysis
Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis.2026PMID:42514320Permalink